Posted on August 12th, 2015 by
Class: Supportive Care
Generic Name: Zoledronic acid
Trade Name: Reclast®
For which conditions is this drug approved? Reclast is FDA approved for the treatment and prevention of postmenopausal osteoporosis, to increase bone mass in men with osteoporosis, and to treat and prevent glucocorticoid-induced osteoporosis. People with rheumatoid arthritis (RA) may be at increased rick for osteoporosis, in part because glucocorticoids are often used in their treatment. Rheumatoid arthritis itself might also cause bone loss. In addition, people who are in pain and have reduced joint function due to RA might be less active, which increases risk of bone loss. (Reclast is also approved to treat Paget’s disease, a condition that causes rapid isolated bone repair and a variety of symptoms—from softer bones to enlarged bone growth.)
What is the mechanism of action? Reclast is a type of drug known as a bisphosphonate. Bisphosphonates reduce bone loss by inhibiting osteoclasts (cells that break down bone).
How is Reclast typically given (administered)? Reclast is given intravenously (into a vein). The frequency of administration depends on the purpose of treatment. For the treatment of osteoporosis, Reclast is generally given once per year.
How are patients typically monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Reclast. Patients may undergo blood tests, physical examinations, scans, or other measures to assess side effects and response to therapy.
What serious side effects can occur with Reclast?
What are the most common side effects of treatment with Reclast?
This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.
Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?
Are there any special precautions patients should be aware of before starting treatment?
When should patients notify their physician?
Tell your doctor if you experience any unusual symptoms. Notify your healthcare provider immediately if you experience symptoms of hypocalcemia (low calcium levels), such as muscle spasms, twitches, or cramps, or numbness or tingling in fingers, toes, or the area around your mouth. You should also notify your doctor if you experience symptoms of a fracture or severe bone, joint, or muscle pain. Because Reclast should not be used if you are pregnant, inform your doctor if you become pregnant or plan to become pregnant.
What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.
You must be logged-in to the site to post a comment.